Lift Global Ventures plc (AQSE:LFT), an investment and acquisition company focused on foundational artificial intelligence, announced that it has completed a strategic investment in FourJaw Manufacturing Analytics Ltd, a UK scale-up applying cutting edge technologies, AI and machine learning to one of manufacturing’s biggest challenges: unlocking productivity from the factory floor.
Acquisition of 35,178 shares in FourJaw, representing 2.18% of FourJaw’s issued share capital, for a total consideration of £150,000. Consideration satisfied entirely in equity through the issue of 10,000,000 new ordinary shares in the Company at a value of 1.5p per share, preserving the Company’s cash resources FourJaw is a spinout from the University of Sheffield’s Advanced Manufacturing Research Centre (AMRC). Its technology is used by more than 150 manufacturers across the UK and internationally. The investment further advances Lift’s strategy of building a global centre for applied AI innovation alongside Yorkshire AI Labs LLP.
Comment: Perhaps a more canny deal than anyone in the market might have expected from LFT, especially the 1.5p share price. The issue with such deals is that good investee companies tend to demand high valuations leaving the investor with only a small slug of shares, and hence unless they deliver say, a 10x upside plus, the exercise can be of marginal impact. Note the difference between the initial 0.5p share price today and the 1.5p deal level. It will be interesting to see whether this differential narrows as the market digests the news. Well done on giving LFT shares to FourJaw at 4x the preannouncement share price, they must be good people. It may have helped that two LFT board members already held shares in FourJaw?
DeFi Development Corporation (DFDV) is changing its name to Cykel AI PLC to reflect a strategic repositioning towards artificial intelligence. The company has secured an extension until June 29, 2028, for investors to satisfy conditions related to warrants from a £2.8 million fundraise announced in August 2025. Additionally, the company’s revolving credit facility has been terminated with a settlement payment made, and Hadley Stern, Michael Chan, and Nathalie Maggi are stepping down from their board positions, with Gerald Tritt appointed as the new Chief Executive Officer. (Investegate)
Comment: DeDi was such a cool name, it is a shame to get rid of it. Of more interest is the sharp share price rise associated with the settlement payment and the implied cloud of uncertainty that has been removed in its wake.
Futura Medical (FUM), the consumer healthcare Group behind Eroxon® that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, today provides an update on its commercial partner status for Eroxon® in the US market. Further to the initial announcement on 13 November 2025 and as outlined in subsequent announcements, in which the Company stated that it was in conversations with Haleon relating to alternative, potentially third party, commercial and distribution strategies and arrangements, the Company has terminated its agreement with Haleon. The Company has also reached an agreement with an alternative distribution partner, Market Performance Group, to distribute Eroxon® in the US. MPG is a leading omnichannel commerce agency that helps brands accelerate profitable growth across retail and eCommerce channels and serving as a trusted partner to many leading health and wellness brands in the US.
Comment: It has been notable that shares of FUM have been bubbling under in recent days, almost as if someone, somewhere successfully guessed that today’s no money value deal would be announced. Indeed, it could be that this is a decent way of sugar coating the end of the Haleon agreement.
Solid State (SOLI) reported a strong financial year ended March 31, 2026, with revenue increasing by 23.2% to £154.1 million and adjusted operating profit rising by 60.0% to £9.6 million, leading to an adjusted diluted earnings per share of 11.0p, up from 6.2p in the prior year. The company also saw its net debt decrease by 43.24% to £4.2 million, and the proposed full-year dividend increased by 10.0% to 2.75p per share. Performance was driven by robust demand in the defence and security sector, which accounted for 47% of revenue, and significant growth in the Systems division, up 47.8% to £62.5 million. The Group anticipates exceeding market expectations for the upcoming fiscal year. (Investegate)
Comment: Although the debt level has risen, the market seems to be enamoured enough with SOLI to allow the share price to move towards the best levels of the year near 210p. Above this on a weekly basis one would be looking for 2 year resistance at 300p plus by the autumn.
SkinBioTherapeutics plc, (SBTX), the life science business focused on skin health, will be presenting to shareholders at 09.00 BST today, Monday 29 June 2026 on the Investor Meet Company platform. The presentation will be led by Alyson Levett, Acting Chair and Rachel Parsonage, Interim CEO. The presentation will be brief and cover recent post period events, the investigation and the disclosable information from the FRP Advisory report, before running through the recent HY26 results, post period trading and outlook. The Company will also be stating that the FY26 results will be prepared on a going concern basis.
Comment: Rather counterintuitively, we have seen a very strong set up on the SBTX daily chart, and perhaps even more so the shares have rallied in accordance with this. One wonders whether the implied 19p chart target could actually be hit by the end of next month?
Eco (Atlantic) Oil & Gas Ltd. (ECO), the oil and gas exploration company focused on the offshore Atlantic Margins, announced that it has received formal Ministerial approval from the Ministry of Industries, Mines and Energy of Namibia for the Section 11 assignment relating to the Company’s previously announced farm-out of its 85% participating interest in Petroleum Exploration Licence 98, offshore Namibia, to an arm’s-length wholly Namibian-owned company, Lamda Energy (Pty) Ltd
Comment: ECO has this year certainly ridden the tiger of Atlantic Margin mania, with the share price skyrocketing. What will be interesting to see now is whether with the oil price weaker some in the stock decide to head for the exit rather than waiting for the next breakthrough on the fundamental front.
genedrive plc (GDR), the point-of-care pharmacogenetic testing company, announced a collaboration agreement with Thermo Fisher Scientific Inc. enabling genedrive to develop a CYP2C19 pharmacogenetic in vitro diagnostic (“IVD”) test for deployment on Thermo Fisher Scientific’s QuantStudio™ 5 Dx real-time PCR laboratory platform (the Genedrive® CYP2C19 HT Kit). The Genedrive® CYP2C19 HT Kit is designed for centralised, high-throughput laboratory testing, addressing a different market segment to the Company’s rapid Genedrive® CYP2C19 ID Kit, which targets near-patient settings.
Comment: Almost by stealth GDR has been one of the year’s better biotech winners, a state of affairs that looks set to continue. It would appear that after many years, and lots of cash raised the company is on its way, more fundraises notwithstanding. This year’s 51% share price is certainly not shabby.
Gunsynd Plc (GUN) provided an update on the Barb Gold Project in Manitoba, Canada, further to the Company’s announcement of 4 June 2026. As per the announcement on 4 June 2026, Gunsynd engaged Critical Discoveries to complete the Phase 1 Summer Field Program targeting the Lotus and Betty Shaft areas, comprising grab sampling and mineralisation characterisation of the prospects. 59 samples were collected across the two historic showings with grades ranging from 0.008 – 489 g/t. Gold-bearing mineralisation was observed at both locations with 35 samples assaying above 1 g/t, 23 above 5 g/t and 3 above 100 g/t Au. Rock samples were collected as fist-sized grab samples from locations where mineralisation was observed. Gold assay results are reported as Au (g/t) and were determined by fire assay with gravimetric finish. Multi-element geochemical results are pending.
Comment: The market has been rather hard on GUN, especially since its transformation from an investment company to rolling its sleeves up as an explorer developer. The thing to note here is that the management is great at spotting opportunities, as today’s update / grades underlines. One would think that the 0.1p zone will be a lasting support zone for the shares, given the above.
Tap Global Group plc (TAP), an innovative digital finance hub that brings money payments and crypto settlement services together in a single user-friendly app, announced the launch of Stabld, the Group’s own stablecoin, live within the Tap app’s Earn product from today. This is the first step in a broader initiative the Group describes as “the settlement layer for modern money”. By owning both the stablecoin and the rails that move it, Tap can control every on- and off-ramp end-to-end resulting in seamless 1:1 conversion, instant settlement across the payment networks it connects to, and – through its B2B business – that same instant settlement for other companies, turning Tap’s own infrastructure into a product that wins new customers.
Comment: Another decent sounding initiative from TAP, with the only problem being that all most shareholders currently care about is the share price underpeformance. They may also be concerned that the ongoing slide in cryptos will scupper the initiatives as sentiment towards the asset class continues to wane after the initial Trump Presidency hype.
Porvair plc (PORV), the specialist filtration, laboratory and environmental technology group, announced its interim results for the six months ended 31 May 2026. PORV said “The Group delivered both record revenue and profit in the first half, reflecting disciplined execution and the strength and resilience of Porvair’s diversified portfolio against mixed conditions across the Group’s end markets. Strength in aerospace, nuclear, life sciences, aluminium and superalloys was partially offset by expected weakness in petrochemicals and certain industrial end markets.”
Comment: Shares of PORV are surprisingly still off their initial 2026 peaks through 900p, which seems rather unfair given the way that the performance of the company is at record levels. Presumably this anomaly will be rectified in short order.
Creo Medical Group plc (CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, provides an update to shareholders ahead of its Annual General Meeting (“AGM”). CREO said “As previously reported, the FY25 growth momentum has continued into FY26 with strong trading performance in the first three months of the current financial year. Year-on-year revenue growth (Q1 FY26 vs Q1 FY25) was approximately 60%, at the higher end of management’s expectations, reflecting continued customer adoption, growing procedural volumes and further conversion of the Group’s commercial pipeline into revenue across our key markets. As set out in our FY25 Results, this strong performance underpins the Board’s confidence in the ongoing growth of the business and we believe that full year FY26 revenue growth will be between 50% and 60% compared to FY25 (previous guidance was between 40% and 60% growth).”
Comment: Shares of CREO delivered a sharp gap to the upside both last month and earlier in June, something which indicates the handbrake turn change in the perception of the company. Now with today’s update out of the way, we should see further improvements in the stock, with 2026 resistance towards 18p on the cards as soon as the end of August.
Disclaimer & Declaration of Interest:
The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.
